Advertisement

Biological Trace Element Research

, Volume 155, Issue 1, pp 1–4 | Cite as

Effect of Chromium-Enriched Yeast on Fasting Plasma Glucose, Glycated Haemoglobin and Serum Lipid Levels in Patients with Type 2 Diabetes Mellitus Treated with Insulin

  • Jaroslav Racek
  • C. D. SindbergEmail author
  • S. Moesgaard
  • Josef Mainz
  • Jaroslav Fabry
  • Luděk Müller
  • Katarína Rácová
Article

Abstract

Chromium is required for a normal insulin function, and low levels have been linked with insulin resistance. The aim of this study was to follow the effect of chromium supplementation on fasting plasma glucose (FPG), glycated haemoglobin (HbA1c) and serum lipids in patients with type 2 diabetes mellitus (DM2) on insulin therapy. Eleven randomly selected patients with DM2 on insulin therapy were supplemented with a daily dose of 100 μg chromium yeast for the first supplementation period of 2 weeks. In the second supplementation period, the chromium dose was doubled and continued for the next 6 weeks. The third phase was a 6-week washout period. After each period, the levels of FPG and HbA1c were compared with the corresponding values at the end of the previous period. Serum triglycerides, total HDL and LDL cholesterol values after supplementation were compared with the baseline values. FPG decreased significantly after the first period of chromium supplementation (p < 0.001), and a tendency to a further reduction was observed after the second supplementation period. Similarly, HbA1c decreased significantly in both periods (p < 0.02 and p < 0.002, respectively). Eight weeks after withdrawal of chromium supplementation, both FPG and HbA1c levels returned to their pre-intervention values. The serum lipid concentrations were not significantly influenced by chromium supplementation. Chromium supplementation could be beneficial in patients with DM2 treated with insulin, most likely due to lowered insulin resistance leading to improved glucose tolerance. This finding needs to be confirmed in a larger study.

Keywords

Chromium Diabetes mellitus (DM2) Glycated haemoglobin (HbA1cFasting plasma glucose (FPG) Insulin resistance Serum lipids 

Notes

Conflict of Interest

Pharma Nord ApS, Vejle, Denmark provided the research preparations free of charge. Apart from this, the authors declare that they have no conflict of interest.

References

  1. 1.
    Vincent JB (2004) Recent advances in the nutritional chemistry of trivalent chromium. Proc Nutr Soc 63:41–47PubMedCrossRefGoogle Scholar
  2. 2.
    Vincent JB (2000) The biochemistry of chromium. J Nutr 130:715–718PubMedGoogle Scholar
  3. 3.
    Balk EM, tatsioni A, Lichtenstein AH, Lau J, Pittas AG (2007) Effect of chromium supplementation on glucose metabolism and lipids. A systematic review of randomized controlled trials. Diabetes Care 30(8):2154–2163PubMedCrossRefGoogle Scholar
  4. 4.
    Anderson RA, Cheng N, Bryden NA, Polansky MM, Cheng N, Chi J, Feng J (1997) Elevated intakes of supplemental chromium improve glucose and insulin variables in individuals with type 2 diabetes. Diabetes 46:1786–1791PubMedCrossRefGoogle Scholar
  5. 5.
    Anderson RA (2000) Chromium in the prevention and control of diabetes. Diabetes Metab 26:22–27PubMedGoogle Scholar
  6. 6.
    Bahijiri SM, Mira SA, Mufti AM, Ajabnoor MA (2000) The effects of inorganic chromium and brewer’s yeast supplementation on glucose tolerance, serum lipids and drug dosage in individuals with type 2 diabetes. Saudi Med J 21:831–837PubMedGoogle Scholar
  7. 7.
    Racek J, Trefil L, Rajdl D, Mudrova V, Hunter D, Senft V (2006) Influence of chromium-enriched yeast on blood glucose and insulin variables, blood lipids, and markers of oxidative stress in subjects with type 2 diabetes mellitus. Biol Trace Elem Res 109:215–230PubMedCrossRefGoogle Scholar
  8. 8.
    Mužík P, Mainz J, Huml O, Sindberg CD, Moesgaard S (2011) Diabetes mellitus in dogs and cats—clinical experience with bioactive chromium supplementation in dogs treated with insulin. EJCAP 21:62–67Google Scholar
  9. 9.
    Offenbacher EG, Pi-Sunyer FX (1980) Beneficial effect of chromium-rich yeast on glucose tolerance and blood lipids in elderly subjects. Diabetes 29:919–925PubMedCrossRefGoogle Scholar
  10. 10.
    Rabinowitz MB, Gonick HC, Levin SR, Davidson MB (1983) Effects of chromium and yeast supplements on carbohydrate and lipid metabolism in diabetic men. Diabetes Care 6:319–327PubMedCrossRefGoogle Scholar
  11. 11.
    Grant AP, McMullen JK (1982) The effect of brewers yeast containing glucose tolerance factor on the response to treatment in type 2 diabetics: a short controlled study. Ulster Med J 51:110–114PubMedGoogle Scholar
  12. 12.
    Król E, Krejpcio Z, Byks H, Bogdański P, Pupek-Musialik D (2011) Effects of chromium brewer's yeast supplementation on body mass, blood carbohydrates, and lipids and minerals in type 2 diabetic patients. Biol Trace Elem Res 143:26–737CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Jaroslav Racek
    • 1
  • C. D. Sindberg
    • 2
    Email author
  • S. Moesgaard
    • 2
  • Josef Mainz
    • 3
  • Jaroslav Fabry
    • 4
  • Luděk Müller
    • 5
  • Katarína Rácová
    • 6
  1. 1.Institute of Clinical Biochemistry and HematologyCharles University in Prague, Medical Faculty and Faculty Hospital in PilsenPragueCzech Republic
  2. 2.Pharma Nord ResearchVejleDenmark
  3. 3.Pharma Nord Praha s. r. o.PragueCzech Republic
  4. 4.Diafa, s. r. o.BratislavaSlovak Republic
  5. 5.Department of Cybernetics, Faculty of Applied SciencesUniversity of West BohemiaPilsenCzech Republic
  6. 6.Department of Clinical BiochemistrySt. Elisabeth Cancer InstituteBratislavaSlovak Republic

Personalised recommendations